Vertaling van "thromboembolism on risk " (Frans → Nederlands) :

(Jick 2006) Jick SS, Kaye JA, Russmann S, Jick H. Risk of nonfatal venous thromboembolism with oral contraceptives containing
(Jick 2006) Jick SS, Kaye JA, Russmann S, Jick H. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or

Risk of non-fatal venous thromboembolism in women using oral contraceptives containing
Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone

(Lidegaard 2011) Lidegaard Ø, Hougaard L, Wessel Skovlund C et al. Risk of venous thromboembolism from use of oral
(Lidegaard 2011) Lidegaard Ø, Hougaard L, Wessel Skovlund C et al. Risk of venous thromboembolism from use of oral contraceptives

Risk of venous thromboembolism in users of oral contraceptives
Risk of venous thromboembolism in users of oral contraceptives containing

Boutitie F, Pinede L, Schulman S et al. Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participant’s data from seven trials. BMJ 2011; 342:d3036.
Campbell IA, Bentley DP, Prescott RJ et al. Anticoagulation for three versus six months in patients with deep vein thrombosis or pulmonary embolism, or both; randomized trial.

(Vasilakis-Scaramozza 2001) Vasilakis-Scaramozza C, Jick H. Risk of venous thromboembolism with cyproterone or
(Vasilakis-Scaramozza 2001) Vasilakis-Scaramozza C, Jick H. Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives.